SCCORE PHARMAS UK LIMITED

SCCORE PHARMAS UK LIMITED
Contents Page
For the Period 17 July 2025 to 31 July 2026

Statement of Financial Position	1
Notes to the Financial Statements	2

SCCORE PHARMAS UK LIMITED
Statement of Financial Position
As at 31 July 2026

	Notes	2026 £
Current assets
Cash at bank and in hand		100
Creditors: amount falling due within one year		(1,230)
Net current assets		(1,130)

Total assets less current liabilities		(1,130)
Net assets		(1,130)

Capital and reserves
Called up share capital		100
Profit and loss account		(1,230)
Shareholders' funds		(1,130)

For the period ended 31 July 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).

The financial statements were approved by the board of directors on 21 August 2026 and were signed on its behalf by:

-------------------------------
Angarika Ravindra Raul
Director

1

SCCORE PHARMAS UK LIMITED
Notes to the Abridged Financial Statements
For the Period 17 July 2025 to 31 July 2026

General Information

SCCORE PHARMAS UK LIMITED is a private company, limited by shares, registered in England and Wales, registration number 16587965, registration address 11, Winckley Close, Harrow, HA3 9QW.

The presentation currency is £ sterling.

1.

Accounting policies

Significant accounting policies

Statement of compliance

These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

Basis of preparation

The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.

The financial statements are prepared in sterling which is the functional currency of the company.

Turnover

Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.

Taxation

Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted

Deferred taxation

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the reporting date.
Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
Current and deferred tax assets and liabilities are not discounted.

2.	Average number of employees Average number of employees during the period was 0.

2

Registered Number: 16587965
England and Wales
SCCORE PHARMAS UK LIMITED

Abridged Accounts

Period of accounts Start date: 17 July 2025 End date: 31 July 2026